Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

An Open-label, Multi-center, Phase I/II Study of ECI830 as a Single Agent and in Combination With Ribociclib and Endocrine Therapy in Patients With Advanced Hormone Receptor Positive, HER2-negative Breast Cancer and Advanced Solid Tumors

Phase I: Characterize safety and tolerability of ECI830 as a single agent and in combination with ribociclib and fulvestrant. Identify dose range for optimization/recommended dose for future studies.

Phase II: Assess the anti-tumor activity of ECI830 in combination with ribociclib and fulvestrant in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer.

Study Overview

• Status: Recruiting
• Conditions: Advanced HR+/HER2- Breast Cancer; Advanced CCNE1-amplified Solid Tumors
• Intervention / Treatment: Drug: ECI830; Drug: ribociclib; Drug: fulvestrant

Detailed Description

This is a first-in-human, open-label, phase I/II, multi-center study consisting of an ECI830 single agent treatment arm in patients with advanced HR+/HER2- breast cancer or other advanced solid tumors harboring CCNE1 amplification and a combination treatment arm of ECI830 with ribociclib and fulvestrant in patients with advanced breast cancer. Single agent escalation may be followed by an expansion part stratified by disease indication. The escalation of the combination arm may continue into a randomized, open label, Phase II with optional dose optimization in advanced breast cancer patients.

• Study Type: Interventional
• Enrollment (Estimated): 280
• Phase: Phase 2; Phase 1

Expanded Access

Available outside the clinical trial. See expanded access record.

Contacts and Locations

• Study Contact: Name: Novartis Pharmaceuticals; Phone Number: 1-888-669-6682; Email: novartis.email@novartis.com
• Study Contact Backup: Name: Novartis Pharmaceuticals; Phone Number: +41613241111; Email: novartis.email@novartis.com

Study Locations

• Australia
  • Victoria
    • Clayton, Victoria, Australia, 3168
      • Recruiting
      • Novartis Investigative Site
    • Melbourne, Victoria, Australia, 3004
      • Recruiting
      • Novartis Investigative Site
• Canada
  • Ontario
    • Toronto, Ontario, Canada, M5G 2M9
      • Recruiting
      • Novartis Investigative Site
  • Quebec
    • Montreal, Quebec, Canada, H4A 3J1
      • Recruiting
      • Novartis Investigative Site
• China
  • Jiangsu
    • Nanjing, Jiangsu, China, 210029
      • Recruiting
      • Novartis Investigative Site
  • Shanxi
    • Xian, Shanxi, China, 710061
      • Recruiting
      • Novartis Investigative Site
• Czechia
  • Brno, Czechia, 656 53
    • Recruiting
    • Novartis Investigative Site
• Denmark
  • Copenhagen, Denmark, DK-2100
    • Recruiting
    • Novartis Investigative Site
  • Odense C, Denmark, 5000
    • Recruiting
    • Novartis Investigative Site
• France
  • Bordeaux, France, 33076
    • Recruiting
    • Novartis Investigative Site
  • Saint-Herblain, France, 44805
    • Recruiting
    • Novartis Investigative Site
• Germany
  • Heidelberg, Germany, 69120
    • Recruiting
    • Novartis Investigative Site
  • Ulm, Germany, 89081
    • Recruiting
    • Novartis Investigative Site
  • Baden-Wurttemberg
    • Freiburg im Breisgau, Baden-Wurttemberg, Germany, 79106
      • Recruiting
      • Novartis Investigative Site
• Israel
  • Haifa, Israel, 3109601
    • Recruiting
    • Novartis Investigative Site
  • Tel Aviv, Israel, 6423906
    • Recruiting
    • Novartis Investigative Site
• Italy
  • Milan, Italy, 20141
    • Recruiting
    • Novartis Investigative Site
  • MO
    • Modena, MO, Italy, 41124
      • Recruiting
      • Novartis Investigative Site
• Japan
  • Tokyo
    • Chuo Ku, Tokyo, Japan, 1040045
      • Recruiting
      • Novartis Investigative Site
• Singapore
  • Singapore, Singapore, 119074
    • Recruiting
    • Novartis Investigative Site
• South Korea
  • Seoul, South Korea, 03080
    • Recruiting
    • Novartis Investigative Site
• Spain
  • Barcelona, Spain, 08035
    • Recruiting
    • Novartis Investigative Site
  • Barcelona, Spain, 08036
    • Recruiting
    • Novartis Investigative Site
• Taiwan
  • Tainan, Taiwan, 704
    • Recruiting
    • Novartis Investigative Site
• United Kingdom
  • Oxford
    • London, Oxford, United Kingdom, OX3 7LE
      • Recruiting
      • Novartis Investigative Site
• United States
  • California
    • Los Angeles, California, United States, 90095
      • Recruiting
      • University of California LA
      • Principal Investigator: Saeed Sadeghi
      • Contact: Rika Galias; Phone Number: 310-794-4376; Email: rgalias@mednet.ucla.edu
  • Florida
    • Fort Myers, Florida, United States, 33901
      • Recruiting
      • Florida Cancer Specialists
      • Principal Investigator: Manish Patel
      • Contact: Pacia Eckert; Phone Number: 941-377-9993; Email: pacia.eckert@flcancer.com
  • Massachusetts
    • Boston, Massachusetts, United States, 02115
      • Recruiting
      • Dana Farber Cancer Institute
      • Principal Investigator: Antonio Giordano
      • Contact: Jocelyn Tierney; Phone Number: 617-632-5136; Email: jocelyn_tierney@dfci.harvard.edu
  • Missouri
    • St Louis, Missouri, United States, 63110
      • Recruiting
      • WA Uni School Of Med
      • Principal Investigator: Cynthia Ma
      • Contact: Mary Halim; Phone Number: 314-362-7249; Email: maryh@wustl.edu
  • New York
    • New York, New York, United States, 10017
      • Recruiting
      • Memorial Sloan Kettering
      • Principal Investigator: Komal Jhaveri
      • Contact: Josie Anderson; Email: andersj@mskcc.org
  • Tennessee
    • Nashville, Tennessee, United States, 37203
      • Recruiting
      • SCRI Oncology Partners
      • Principal Investigator: Erika Paige Hamilton
      • Contact: Kristy Long; Email: kristy.long@SCRI.com
  • Texas
    • Houston, Texas, United States, 77030
      • Recruiting
      • MD Anderson Cancer Center Uni of Te
      • Principal Investigator: Timothy Yap
      • Contact: Ileana Gutierrez; Phone Number: 713-792-2848; Email: ilgutierrez@mdanderson.org
  • Washington
    • Seattle, Washington, United States, 98109
      • Recruiting
      • Fred Hutch Cancer Research
      • Principal Investigator: Sara Hurvitz
      • Contact: Ly Tieng Huot; Phone Number: +1 206288 1382; Email: lhuot@fredhutch.org

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

Age ≥ 18 years old.

Patients with one of the following indications:

Phase I:

HR+/HER2- aBC with disease progression on or following at least one line of hormone-based therapy in combination with a CDK4/6i and at least one additional line of systemic therapy for metastatic disease.

Histologically and/or cytologically confirmed diagnosis of locally advanced or metastatic cancer with a CCNE1 amplification. For dose expansion only: no more than 3 prior lines of therapy for advanced or metastatic disease.

Phase II:

HR+/HER2- aBC with disease progression on an aromatase inhibitor or tamoxifen in combination with a CDK4/6 inhibitor for unresectable/metastatic disease with no more than 2 lines of endocrine therapy.

Measurable disease as determined by RECIST v1.1.

BC only: If no measurable disease is present, then at least one predominantly lytic bone lesion must be present that can be accurately assessed at baseline and is suitable for repeated assessment.

Exclusion Criteria:

Previous treatment with a CDK2 inhibitor at any time.

Patients with inadequate bone marrow and/or organ functions with out-of-range laboratory values.

Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality including MI, CABG, long QT syndrome, or risk factors for TdP.

Presence of symptomatic CNS metastases or CNS metastases that require local therapy or increasing doses of corticosteroids within 2 weeks prior to study entry.

For the combination treatment:

Patients with symptomatic visceral disease or any disease burden that makes the patient ineligible for endocrine-based therapy.

Patients who could not tolerate the prescribed dose of ribociclib during a previous course of treatment, requiring dose reduction or permanent discontinuation due to adverse events.

For patients with BC: Patient is concurrently using hormone replacement therapy.

WOCBP who are unwilling to use highly effective contraception methods, pregnant or nursing women.

Other protocol-defined inclusion/exclusion criteria may apply.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: ECI830 Single Agent (Arm A); Phase I	Drug: ECI830; Experimental
Experimental: Dose Escalation Combination ECI830 + ribociclib + fulvestrant (Arm B); Phase I	Drug: ECI830; Experimental; Drug: ribociclib; Approved medication; Other Names: Kisqali; Drug: fulvestrant; Approved medication; Other Names: Faslodex
Experimental: Ribociclib in combination with fulvestrant (Arm C); Phase II	Drug: ribociclib; Approved medication; Other Names: Kisqali; Drug: fulvestrant; Approved medication; Other Names: Faslodex
Experimental: ECI830 in combination with fulvestrant (Arm D); Phase II	Drug: ECI830; Experimental; Drug: fulvestrant; Approved medication; Other Names: Faslodex
Experimental: ECI830 in combination with ribociclib and fulvestrant (Arm E); Phase II	Drug: ECI830; Experimental; Drug: ribociclib; Approved medication; Other Names: Kisqali; Drug: fulvestrant; Approved medication; Other Names: Faslodex
Experimental: ECI830 in combination with ribociclib and fulvestrant (Arm F); Phase II	Drug: ECI830; Experimental; Drug: ribociclib; Approved medication; Other Names: Kisqali; Drug: fulvestrant; Approved medication; Other Names: Faslodex

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Phase I: Incidence of dose-limiting toxicities (DLTs)	A DLT is defined as an adverse event or abnormal laboratory value of Common Terminology Criteria for Adverse Events (CTCAE) grade ≥ 3 assessed as unrelated to disease, disease progression, inter-current illness or concomitant medications that occurs within the first 28 days of treatment. Other clinically significant toxicities may be considered to be DLTs, even if not CTCAE grade 3 or higher.	2 years
Phase I: Incidence of adverse events (AEs) and serious adverse events (SAEs)	Number of participants with AEs and SAEs by treatment group, including changes in vital signs, electrocardiograms (ECGs) and laboratory results qualifying and reported as AEs.	2 years
Phase I: Number of participants with dose interruptions, reductions and discontinuations	Assessment of tolerability. For patients who do not tolerate the protocol-specified dosing schedule, dose adjustments are permitted in order to allow patients to continue the study treatment.	2 years
Phase II: PFS rate at 6 months per local response evaluation criteria in solid tumors (RECIST) v1.1	Progression Free Survival (PFS) rate at 6 months is defined as the proportion of patients who are alive and progression-free per RECIST v1.1 at 6 months.	6 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Phase I and II: Area under the plasma concentration-time curve (AUC) of ECI830 and ribociclib	Pharmacokinetic (PK) parameters calculated based on ECI830 and ribociclib plasma concentrations by using non-compartmental methods.	From pre-dose up to 24 hours post-dose in Cycle 1. One cycle=28 days.
Phase I and II: Maximum observed plasma concentration (Cmax) of ECI830 and ribociclib	PK parameters calculated based on ECI830 and ribociclib plasma concentrations by using non-compartmental methods.	From pre-dose up to 24 hours post-dose in Cycle 1. One cycle=28 days.
Phase I and II: Best overall response (BOR) per RECIST v1.1	BOR per RECIST v1.1 is defined as the best overall confirmed response recorded from the start of the treatment until progressive disease (PD), death, start of new therapy, withdrawal of consent or end of study, whatever comes first.	2 years
Phase I and II: Overall response rate (ORR) per RECIST v1.1	ORR per RECIST v1.1 is defined as the proportion of patients with a BOR of Complete response (CR) or Partial response (PR) according to RECIST v1.1 as per local review.	2 years
Phase I and II: Disease control rate (DCR) per RECIST v1.1	DCR per RECIST v1.1 is defined as the proportion of patients with a BOR of CR, PR, or Stable disease (SD) according to RECIST v1.1 as per local review.	2 years
Phase I and II: Clinical benefit rate (CBR) per RECIST v1.1	CBR per RECIST v1.1 is defined as the proportion of patients with a BOR of CR, PR, or an overall lesion response of SD or Non-CR/Non-PD which lasts for at least 24 weeks according to RECIST v1.1 as per local review.	2 years
Phase I and II: Progression Free Survival (PFS) per RECIST v1.1	PFS is defined as the time from the date randomization to the date of the first documented progression or death due to any cause.	2 years
Phase II: Duration of Response (DOR) per RECIST v1.1	DOR per RECIST v1.1 is the time between the first documented response (CR or PR) and the date of progression or death due to any cause.	2 years
Phase II: Overall Survival (OS)	OS is defined as the time between the date of randomization to the date of death due to any cause.	2 years
Phase II: Incidence of adverse events (AEs) and serious adverse events (SAEs)	Number of participants with AEs and SAEs by treatment group, including changes in vital signs, electrocardiograms (ECGs) and laboratory results qualifying and reported as AEs.	2 years
Phase II: Number of participants with dose interruptions, reductions and discontinuations	Assessment of tolerability. For patients who do not tolerate the protocol-specified dosing schedule, dose adjustments are permitted in order to allow patients to continue the study treatment.	2 years

Collaborators and Investigators

• Sponsor: Novartis Pharmaceuticals

Study record dates

Study Major Dates

• Study Start (Actual): April 3, 2025
• Primary Completion (Estimated): September 25, 2028
• Study Completion (Estimated): September 25, 2028

Study Registration Dates

• First Submitted: December 5, 2024
• First Submitted That Met QC Criteria: December 5, 2024
• First Posted (Actual): December 10, 2024

Study Record Updates

• Last Update Posted (Actual): April 27, 2026
• Last Update Submitted That Met QC Criteria: April 24, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Keywords: Breast cancer; Ribociclib; Fulvestrant; CCNE1 amplification; ECI830
• Additional Relevant MeSH Terms: Neoplasms by Site; Neoplasms; Skin Diseases; Breast Diseases; Skin and Connective Tissue Diseases; Breast Neoplasms; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Polycyclic Compounds; Steroids; Fused-Ring Compounds; Estradiol; Estrenes; Estranes; Estradiol Congeners; Gonadal Steroid Hormones; Gonadal Hormones; Fulvestrant; ribociclib
• Other Study ID Numbers: CECI830A12101; 2024-517281-42 (Registry Identifier: CTIS)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No